Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
Protagonist Therapeutics develops peptide-based therapeutics using a proprietary discovery platform, with programs spanning inflammation and immunology, hematology and metabolic disease. Company news centers on ICOTYDE™ (icotrokinra), an oral IL-23 receptor-targeted peptide approved for moderate-to-severe plaque psoriasis, and rusfertide, a hepcidin mimetic peptide for polycythemia vera developed with Takeda.
Recurring updates also cover collaboration economics with Johnson & Johnson's Janssen Biotech and Takeda, clinical and regulatory milestones, R&D spending on wholly owned discovery programs, financial results, investor conference participation and equity-based inducement awards under Nasdaq rules.
Protagonist Therapeutics (Nasdaq: PTGX) announced a virtual presentation by Dr. Dinesh V. Patel at the J.P. Morgan Healthcare Conference on January 11, 2022, at 2:15 a.m. EST. Dr. Patel will also participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. Both events will be accessible via the company's Investors website. Protagonist is advancing multiple peptide-based therapies, including rusfertide (PTG-300) for polycythemia vera and PN-943 for ulcerative colitis, along with collaboration on PN-235 with Janssen Biotech.
Protagonist Therapeutics (PTGX) presented promising data from two ongoing Phase 2 studies of rusfertide for polycythemia vera (PV) at the ASH 2021 Annual Meeting. Results show that 84% of patients eliminated the need for phlebotomy, with rapid hematocrit control observed. The Phase 3 trial is set to begin in early 2022.
Notably, the drug was well tolerated, with minimal severe adverse events reported. Rusfertide may also have implications in treating hereditary hemochromatosis.
Protagonist Therapeutics (Nasdaq: PTGX) has announced that Dinesh V. Patel, CEO, will present at the JMP Securities Hematology and Oncology Summit on December 6, 2021, at 1:40 p.m. EST. A webcast will be available for 90 days on the company’s Investors website. Protagonist focuses on peptide-based therapeutics, including rusfertide (PTG-300) for polycythemia vera and PN-943 for ulcerative colitis. They also collaborate with Janssen Biotech on oral IL-23 receptor antagonists. This upcoming presentation marks a key moment for stakeholders and potential investors.
Protagonist Therapeutics (Nasdaq: PTGX) announced PN-235 as its main candidate for clinical studies, focusing on the IL-23 pathway, following a collaboration with Janssen. The Phase 2 study for psoriasis is set to begin in early 2022, along with new studies for inflammatory bowel diseases expected later. Protagonist will earn $25 million for the psoriasis study and is eligible for $900 million in future milestones. The company will discontinue PN-232 in favor of PN-235 due to its superior profile.
Protagonist Therapeutics (PTGX) announced promising results from a Phase 2a study for rusfertide, aimed at treating hereditary hemochromatosis (HH), a genetic disorder causing excessive iron absorption. The study involved 16 patients and demonstrated significant reductions in therapeutic phlebotomy requirements and improved serum iron levels. Rusfertide exhibited a favorable safety profile, with most adverse events being mild. This marks a critical step towards developing the first-in-class therapy for HH, addressing unmet medical needs for patients unable to undergo traditional phlebotomy.
Protagonist Therapeutics (Nasdaq: PTGX) announced that CEO Dinesh V. Patel, Ph.D., will present and engage in one-on-one investor meetings at the Jefferies London Healthcare Conference on November 18, 2021, and the Piper Sandler 33rd Annual Healthcare Conference on November 22, 2021. The Jefferies event is scheduled for 3 a.m. EST, while the Piper Sandler event will begin at 10 a.m. EST. A webcast will be available for 90 days on Protagonist's website. The company focuses on peptide-based therapies, including treatments for conditions like polycythemia vera and ulcerative colitis.
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) has announced that two abstracts detailing updated data from its Phase 2 study of rusfertide in polycythemia vera (PV) will be presented orally at the ASH 2021 Annual Meeting from December 11-14. The presentations, scheduled for December 12, will showcase rusfertide's effectiveness in controlling hematocrit levels and reducing the need for phlebotomy. Additionally, three other abstracts will be presented as posters. Protagonist aims to advance rusfertide into a Phase 3 trial in early 2022.
Protagonist Therapeutics (PTGX) announced its Q3 2021 financial results, revealing a net loss of $33.8 million, or $0.70 per share, compared to a loss of $7.8 million in Q3 2020. The FDA lifted a clinical hold on rusfertide, allowing resumed studies. Notably, Protagonist expects to initiate a Phase 3 study for rusfertide in Q1 2022 and has seen good enrollment in the Phase 2 study of PN-943 for ulcerative colitis. The company maintains sufficient cash reserves of $352.5 million to support operations through 2024.
Protagonist Therapeutics (Nasdaq: PTGX) announced a $7.5 million milestone payment from Janssen Biotech, triggered by the completion of Phase 1 clinical activities for PN-235 (JNJ-2113). This brings the total milestones earned from the collaboration with Janssen to $87.5 million. The collaboration focuses on developing multiple oral IL-23 receptor antagonists for various indications, including inflammatory bowel diseases. Protagonist retains rights to co-detail products for ulcerative colitis and Crohn's disease in the U.S.
Protagonist Therapeutics (Nasdaq: PTGX) announced participation in a fireside chat at the Jefferies Next Generation IBD Therapeutics Summit, scheduled for October 19, 2021. Dinesh V. Patel, Ph.D. and Scott Plevy, M.D. will present, with the session available on-demand from 10:45 a.m. EST. Protagonist is advancing multiple peptide-based therapies, including rusfertide (PTG-300) for conditions like polycythemia vera and hereditary hemochromatosis, and a candidate for ulcerative colitis (PN-943). The company operates from Newark, California.